Answers are grounded in this paper and cite their sources.
Experimental study shows irbesartan reduces oxidative stress and inflammatory markers in diabetic rats, indicating a protective mechanism against renal damage.
OBJECTIVE: To determine the effect of irbesartan on the activity of oxidative stress parameters of glutathione (GSH), superoxide enzyme (SOD) and malondialdehyde (MDA), and concentration of serum inflammatory factors of macrophage chemokine-1 (MCP-1), intercellular adhesion molecule-1 (ICAM-1) and tumor necrosis factor alpha (TNF-∝) in the renal tissue of type 2 diabetic rats. STUDY DESIGN: An experimental study. PLACE AND DURATION OF STUDY: The First People's Hospital of Ningyang County, Shandong Province, China, from April 2017 to March 2018. METHODOLOGY: Thirty healthy male Sprague Dawley rats were randomly divided into a normal control group, a diabetic model group, and an irbesartan treatment group, 10 in each group. Rat models of type 2 diabetes were prepared by highsugar high-fat diet with low-dose streptozotocin injection. Changes in blood glucose and lipids, serum GSH, SOD, MDA, MCP-1, ICAM-1, and TNF-∝ levels were determined. RESULTS: Levels of FBG, TC, TG and LDL, activity of GSH, SOD and MDA, and levels of serum MCP-1, ICAM-1 and TNF-∝ among three groups were statistically significant (all p < 0.001). Compared with the diabetic model group, FBG, TC, TG and LDL levels, MDA activity, MCP-1, ICAM-1 and TNF-∝ levels all decreased in rats of the irbesartan treatment group (all p <0.001), and both GSH and SOD activity increased (both p<0.001). CONCLUSION: Irbesartan can improve blood glucose and lipid levels in type 2 diabetic rats, and reduce renal damage by improving oxidative stress and inhibiting the release of inflammatory cytokines.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: